| Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients (NCT02189577) | Chiesi Farmaceutici S.p.A. | 2014-06-01 |
| Drug-drug Interaction Study of CHF5993 With Cimetidine (NCT02287272) | Chiesi Farmaceutici S.p.A. | 2014-05-01 |
| Triple in Asthma Dose Finding (NCT02127866) | Chiesi Farmaceutici S.p.A. | 2014-04-11 |
| A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler (NCT02148120) | Chiesi Farmaceutici S.p.A. | 2014-04-01 |
| Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device (NCT02119247) | Chiesi Farmaceutici S.p.A. | 2014-04-01 |
| Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD (NCT01917331) | Chiesi Farmaceutici S.p.A. | 2014-03-21 |
| Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER) (NCT01938547) | Chiesi Farmaceutici S.p.A. | 2014-03-17 |
| Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients (NCT02119234) | Chiesi Farmaceutici S.p.A. | 2014-03-01 |
| Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children (NCT01658891) | Chiesi Farmaceutici S.p.A. | 2014-02-01 |
| A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment. (NCT02040597) | Chiesi Farmaceutici S.p.A. | 2014-01-01 |
| Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease (NCT01911364) | Chiesi Farmaceutici S.p.A. | 2014-01-01 |
| An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler DPI (NCT02018549) | Chiesi Farmaceutici S.p.A. | 2013-12-01 |
| A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients (NCT02000609) | Chiesi Farmaceutici S.p.A. | 2013-12-01 |
| Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients (NCT01908712) | Chiesi Farmaceutici S.p.A. | 2013-08-01 |
| Lamazym Aftercare Study (NCT01908725) | Chiesi Farmaceutici S.p.A. | 2013-06-01 |
| beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study (NCT01691677) | Chiesi Farmaceutici S.p.A. | 2013-01-01 |
| Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder (NCT01738087) | Chiesi Farmaceutici S.p.A. | 2012-11-01 |
| A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics (NCT01689571) | Chiesi Farmaceutici S.p.A. | 2012-10-01 |
| First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome (NCT01651637) | Chiesi Farmaceutici S.p.A. | 2012-10-01 |
| Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients (NCT01730404) | Chiesi Farmaceutici S.p.A. | 2012-10-01 |
| Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000 (NCT01651455) | Chiesi Farmaceutici S.p.A. | 2012-09-01 |
| A Study in Patients With Asthma (NCT01570478) | Chiesi Farmaceutici S.p.A. | 2012-07-01 |
| An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device (NCT01651650) | Chiesi Farmaceutici S.p.A. | 2012-06-01 |
| Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase (NCT01602393) | Chiesi Farmaceutici S.p.A. | 2012-05-01 |
| International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison) (NCT01567280) | Chiesi Farmaceutici S.p.A. | 2012-05-01 |
| Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (NCT01577082) | Chiesi Farmaceutici S.p.A. | 2012-04-20 |
| Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (NCT01584505) | Chiesi Farmaceutici S.p.A. | 2012-04-01 |
| Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate (NCT01476813) | Chiesi Farmaceutici S.p.A. | 2012-03-01 |
| Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients (NCT01803087) | Chiesi Farmaceutici S.p.A. | 2012-02-01 |
| Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children (NCT01584492) | Chiesi Farmaceutici S.p.A. | 2011-12-01 |
| Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old (NCT01468272) | Chiesi Farmaceutici S.p.A. | 2011-11-01 |
| Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis (NCT01348243) | Chiesi Farmaceutici S.p.A. | 2011-10-01 |
| Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children (NCT01475032) | Chiesi Farmaceutici S.p.A. | 2011-09-01 |
| Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children (NCT01450774) | Chiesi Farmaceutici S.p.A. | 2011-09-01 |
| A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR) (NCT01351792) | Chiesi Farmaceutici S.p.A. | 2011-09-01 |
| Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV) (NCT01703052) | Chiesi Farmaceutici S.p.A. | 2011-07-01 |
| Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP) (NCT01421056) | Chiesi Farmaceutici S.p.A. | 2011-07-01 |
| Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI (NCT01349257) | Chiesi Farmaceutici S.p.A. | 2011-05-01 |
| Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers (NCT01398111) | Chiesi Farmaceutici S.p.A. | 2011-05-01 |
| A Study in Patients With Chronic Obstructive Pulmonary Disease (NCT01245569) | Chiesi Farmaceutici S.p.A. | 2011-04-12 |
| Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices (NCT01370031) | Chiesi Farmaceutici S.p.A. | 2011-04-01 |
| Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients (NCT01344655) | Chiesi Farmaceutici S.p.A. | 2011-04-01 |
| Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients (NCT01345916) | Chiesi Farmaceutici S.p.A. | 2011-03-01 |
| Prevalence and Reversibility of Lung Hyperinflation in Asthma (NCT01573364) | Chiesi Farmaceutici S.p.A. | 2011-02-01 |
| A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients. (NCT01191424) | Chiesi Farmaceutici S.p.A. | 2010-10-01 |
| Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients (NCT01176747) | Chiesi Farmaceutici S.p.A. | 2010-08-01 |
| Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration (NCT01176903) | Chiesi Farmaceutici S.p.A. | 2010-08-01 |
| Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers (NCT01176851) | Chiesi Farmaceutici S.p.A. | 2010-07-01 |
| Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer (NCT01116089) | Chiesi Farmaceutici S.p.A. | 2010-07-01 |
| Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup (NCT00938353) | Chiesi Farmaceutici S.p.A. | 2010-04-01 |
| Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS) (NCT01102543) | Chiesi Farmaceutici S.p.A. | 2010-03-01 |
| Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma (NCT01070524) | Chiesi Farmaceutici S.p.A. | 2010-01-01 |
| BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate) (NCT00929851) | Chiesi Farmaceutici S.p.A. | 2009-10-01 |
| Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old (NCT01848769) | Chiesi Farmaceutici S.p.A. | 2009-09-01 |
| A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® (NCT01111383) | Chiesi Farmaceutici S.p.A. | 2009-09-01 |
| FACTO Study (Foster® As Complete Treatment Option) (NCT00901368) | Chiesi Farmaceutici S.p.A. | 2009-05-01 |
| A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® (NCT00885365) | Chiesi Farmaceutici S.p.A. | 2009-04-01 |
| Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2) (NCT00861926) | Chiesi Farmaceutici S.p.A. | 2009-03-20 |
| Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients (NCT00868023) | Chiesi Farmaceutici S.p.A. | 2009-02-01 |
| A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma (NCT00862394) | Chiesi Farmaceutici S.p.A. | 2009-02-01 |
| Prospective Study on Asthma Control (NCT01110460) | Chiesi Farmaceutici S.p.A. | 2009-01-01 |
| Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT00782535) | Chiesi Farmaceutici S.p.A. | 2008-12-01 |
| Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers (NCT00777595) | Chiesi Farmaceutici S.p.A. | 2008-10-01 |
| Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD (NCT00640484) | Chiesi Farmaceutici S.p.A. | 2008-04-01 |
| Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI) (NCT01343745) | Chiesi Farmaceutici S.p.A. | 2008-02-01 |
| Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma (NCT00528723) | Chiesi Farmaceutici S.p.A. | 2007-11-01 |
| Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma (NCT00497237) | Chiesi Farmaceutici S.p.A. | 2007-04-01 |
| Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study (NCT00501982) | Chiesi Farmaceutici S.p.A. | 2007-03-01 |
| Foster With or Without Charcoal Block or Aerochamber Plus (NCT01280175) | Chiesi Farmaceutici S.p.A. | 2006-12-01 |
| Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD (NCT00476099) | Chiesi Farmaceutici S.p.A. | 2006-12-01 |
| Dose Finding Study of CHF 4226 for Treating Patients With COPD (NCT00605891) | Chiesi Farmaceutici S.p.A. | 2006-10-01 |
| Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms (NCT00497523) | Chiesi Farmaceutici S.p.A. | 2006-03-01 |
| Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT00972140) | Chiesi Farmaceutici S.p.A. | 2005-08-01 |
| EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (NCT00394368) | Chiesi Farmaceutici S.p.A. | 2004-11-01 |
| Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®) (NCT00413387) | Chiesi Farmaceutici S.p.A. | 2004-09-01 |
| Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD) (NCT00742248) | Chiesi Farmaceutici S.p.A. | 2004-09-01 |
| Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma (NCT00862264) | Chiesi Farmaceutici S.p.A. | 2004-08-01 |
| Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma (NCT00476268) | Chiesi Farmaceutici S.p.A. | 2004-02-01 |
| As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma (NCT00382889) | Chiesi Farmaceutici S.p.A. | 2002-08-01 |
| Expanded Access to Velmanase Alfa (NCT04959240) | Chiesi Farmaceutici S.p.A. | |
| Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients (NCT04552691) | Chiesi Farmaceutici S.p.A. | |